Glenmark

Glenmark’s innovative FDC ‘Indamet’ for effective asthma management
18 Jun

Glenmark’s innovative FDC ‘Indamet’ for effective asthma management

Business CorrespondentBusiness, Health,
Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively. Asthma is a major non-communicable disease that affects more than 34 million people in India, causing thousands of deaths every year. Glenmark became the first company in India to market the innovative FDC of Indacaterol, a…
Read More
Glenmark launched FabiSpray® in partnership with SaNOtize
14 Feb

Glenmark launched FabiSpray® in partnership with SaNOtize

editorBusiness, Health,
A global, innovation-driven pharmaceutical company Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corporation announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray® in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process. FabiSpray®, Nitric Oxide Nasal Spray is designed to kill the COVID-19 virus in the upper airways. Phase 3 trial in India met the key endpoints and demonstrated…
Read More